bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S5 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Scenario-specific projections with sensitivity range in 2020–2050, by cancer site, of female 5-year prevalence count
Notes: (*) the main projection scenario with the dynamic population demographics, incidence rates, and survival rates; Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Figure S4 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Scenario-specific projections with sensitivity range in 2020–2050, by cancer site, of male 5-year prevalence count
Notes: (*) the main projection scenario with the dynamic population demographics, incidence rates, and survival rates; Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Supplementary table S1 from Adherence to the Diabetes Risk Reduction Diet and Bladder Cancer Risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cohort
Authors: Chen Yuanhao , Zeng Song , Jiao Binbin , Zhang He , Li Gao , Zhang Xin , Hu Xiaopeng
Published: December 2023

HRs of the association between DRRD score and the risk of different stage of bladder cancer
Figure S2 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Site-specific 10-year prevalence projections in 2020 and 2050, by sex.
The plot shows the projections for both-sex (A), male (B), and female (C).
Notes: † prevalence count in thousand cases; ‡ percent in all cancers (e.g., sum up to 100%); The y-axis title is ordered based on sex-specific prevalence count in year 2020, with the highest at the top and the lowest at the bottom.
Figure S18 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Decomposed absolute changes over 2020–2050 by cancer site, of female 10-year prevalence count
Notes: Prevalence in year 2020 is used as reference year; Absolute changes in a specific year X is calculated as Prevalence in year X – Prevalence in reference year. Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Figure S16 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Decomposed absolute changes over 2020–2050 by cancer site, of all-sex 10-year prevalence count
Notes: Prevalence in year 2020 is used as reference year; Absolute changes in a specific year X is calculated as Prevalence in year X – Prevalence in reference year. Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Figure S15 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Decomposed absolute changes over 2020–2050 by cancer site, of female 5-year prevalence count
Notes: Prevalence in year 2020 is used as reference year; Absolute changes in a specific year X is calculated as Prevalence in year X – Prevalence in reference year. Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Figure S13 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Decomposed absolute changes over 2020–2050 by cancer site, of all-sex 5-year prevalence count
Notes: Prevalence in year 2020 is used as reference year; Absolute changes in a specific year X is calculated as Prevalence in year X – Prevalence in reference year. Cancer sites are ordered based on sex-specific prevalence count in year 2020 as reading order, with the highest at the top-left and the lowest at the bottom-right corner.
Figure S10 from Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2050: A Statistical Modeling Study
Authors: Nguyen Phuong The , Hori Megumi , Matsuda Tomohiro , Katanoda Kota
Published: December 2023

Time since diagnosed distribution of cancer survivors in 2020 and 2050, by cancer site and sex, of 5-year prevalence count.
The plot presents both-sex (A), male (B), and female (C).
Notes: The y-axis title is ordered based on sex-specific prevalence count in year 2020, with the highest at the top and the lowest at the bottom.
Figure S3 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis
Authors: Al-Muftah Mariam , Al-Ejeh Fares
Published: December 2023

Figure S3: The top cancer sites in the MENA-Arab region leading incidence or mortality in females or males in 2018 for all ages. The MENA-Arab and worldwide ASR in 2018 for incidence for leading cancer sites for all ages in the MENA-Arab countries (coloured bars) and the worldwide rate for these sites (black bars) for females (A) and males (B). Mortality-to-incidence ratio (MIR) for the leading cancer sites in the MENA-Arab countries and the world for females (C) and males (D). Complete data mortality ASRs are available in Tables S1-S2.
Figure S2 from Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis
Authors: Al-Muftah Mariam , Al-Ejeh Fares
Published: December 2023

Figure S2: Mortality-to-incidence ratio (MIR) for five cancers with higher incidence in the Arab region. The MIR was calculated as the ratio of ASR for mortality to the ASR for incidence for all ages. The dotted lines mark the worldwide MIR. Arab countries are colored as those in the Arabian Gulf (maroon), the Levant (green) and North Africa (blue).
Table S3 from Genome-Wide Association and Two-Sample Mendelian Randomization Analyses of Plasma Ghrelin and Gastrointestinal Cancer Risk
Authors: Larsson Susanna C. , Höijer Jonas , Sun Jing , Li Xue , Burgess Stephen , Michaëlsson Karl
Published: December 2023

Studies included in the colorectal cancer consortium dataset used in the present study
Table 1 from Genome-Wide Association and Two-Sample Mendelian Randomization Analyses of Plasma Ghrelin and Gastrointestinal Cancer Risk
Authors: Larsson Susanna C. , Höijer Jonas , Sun Jing , Li Xue , Burgess Stephen , Michaëlsson Karl
Published: December 2023

SNPs associated with plasma ghrelin in GWAS analysis of the discovery and replication cohorts and in both cohorts combined.
Figure S2 from Genome-Wide Association and Two-Sample Mendelian Randomization Analyses of Plasma Ghrelin and Gastrointestinal Cancer Risk
Authors: Larsson Susanna C. , Höijer Jonas , Sun Jing , Li Xue , Burgess Stephen , Michaëlsson Karl
Published: December 2023

Prior and posterior probabilities plots of plasma ghrelin and gastrointestinal cancer in the UK Biobank for genetic variants at the GHRL locus
Figure 1 from Genome-Wide Association and Two-Sample Mendelian Randomization Analyses of Plasma Ghrelin and Gastrointestinal Cancer Risk
Authors: Larsson Susanna C. , Höijer Jonas , Sun Jing , Li Xue , Burgess Stephen , Michaëlsson Karl
Published: December 2023

Associations of plasma ghrelin with gastrointestinal cancer risk in two-sample MR analysis using the primary instrument with four genetic variants. CRC, colorectal cancer. ORs are scaled per approximate doubling of genetically predicted plasma ghrelin. There was evidence of modest heterogeneity in the meta-analysis of colorectal cancer (I2 = 19%), but no heterogeneity between estimates in meta-analyses of the other cancers (I2 = 0%).
Table S3 from Hypothetical Interventions on Diet Quality and Lifestyle Factors to Improve Breast Cancer Survival: The Pathways Study
Authors: Ergas Isaac J. , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Kwan Marilyn L. , Laraia Barbara , Madsen Kristine A. , Yao Song , Thomsen Catherine , Kushi Lawrence H.
Published: December 2023

Baseline characteristics comparing Pathways Study enrolled participants with eligible, unenrolled Kaiser Permanente members
Figure S2 from Hypothetical Interventions on Diet Quality and Lifestyle Factors to Improve Breast Cancer Survival: The Pathways Study
Authors: Ergas Isaac J. , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Kwan Marilyn L. , Laraia Barbara , Madsen Kristine A. , Yao Song , Thomsen Catherine , Kushi Lawrence H.
Published: December 2023

Left column: comparisons of the observed (solid line) vs the natural course (dotted line) estimates by 4-month time intervals from baseline. Right column: differences between observed and natural course estimates (solid line) and 95% pointwise confidence intervals (dotted lines) by 4-month time intervals from baseline.
Figure S1 from Hypothetical Interventions on Diet Quality and Lifestyle Factors to Improve Breast Cancer Survival: The Pathways Study
Authors: Ergas Isaac J. , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Kwan Marilyn L. , Laraia Barbara , Madsen Kristine A. , Yao Song , Thomsen Catherine , Kushi Lawrence H.
Published: December 2023

Steps for estimating risks of all-cause mortality under hypothetical interventions using parametric g-computation
Supplementary Table 1 from Gene–Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia
Authors: Zhong Charlie , Li Shaobo , Arroyo Katti , Morimoto Libby M. , de Smith Adam J. , Metayer Catherine , Ma Xiaomei , Kogan Scott C. , Gauderman W. James , Wiemels Joseph L.
Published: December 2023

Supplementary Table 1: Multivariable AHRR hypomethylation associations between carriers of specific genotypes in dominant and recessive models in the California Cancer Records Linkage Project ALL study 1988-2009.
Supplemental Figure 6 from Gene–Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia
Authors: Zhong Charlie , Li Shaobo , Arroyo Katti , Morimoto Libby M. , de Smith Adam J. , Metayer Catherine , Ma Xiaomei , Kogan Scott C. , Gauderman W. James , Wiemels Joseph L.
Published: December 2023

QQ-plot for CCLS study, non-Hispanic White participants. As Supp. Fig. 4, but for the CCLS non-Hispanic White participant strata.
Supplemental Figure 4 from Gene–Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia
Authors: Zhong Charlie , Li Shaobo , Arroyo Katti , Morimoto Libby M. , de Smith Adam J. , Metayer Catherine , Ma Xiaomei , Kogan Scott C. , Gauderman W. James , Wiemels Joseph L.
Published: December 2023

QQ-plot for CCRLP study, non-Hispanic White participants. Expected P-value distribution is placed on the X-axis, and observed P-values on the Y axis. The plots are displayed as follows: a. 3-degree of freedom test incorporating gene-, environment- and gene x environment interaction, b. gene-ALL test only, c. environment (tobacco)-gene test only, and d. gene x environment (tobacco) interaction p-value only.
Supplemental Figure 3 from Gene–Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia
Authors: Zhong Charlie , Li Shaobo , Arroyo Katti , Morimoto Libby M. , de Smith Adam J. , Metayer Catherine , Ma Xiaomei , Kogan Scott C. , Gauderman W. James , Wiemels Joseph L.
Published: December 2023

Manhattan plot of gene-environment interactions and ALL risk. This figure displays P-values from tobacco X gene interaction only.
Supplemental Table 4 from Educational Attainment and Cancer Incidence in a Large Nationwide Prospective Cohort
Authors: Hodge James M. , Patel Alpa V. , Islami Farhad , Jemal Ahmedin , Hiatt Robert A.
Published: December 2023

Supplemental Table 4 shows hazard ratios and 95% confidence intervals for breast cancer stratified by several clinical factors.
Supplemental Table 3 from Educational Attainment and Cancer Incidence in a Large Nationwide Prospective Cohort
Authors: Hodge James M. , Patel Alpa V. , Islami Farhad , Jemal Ahmedin , Hiatt Robert A.
Published: December 2023

Supplemental Table 3 shows hazard ratios and 95% confidence intervals for prostate cancer stratified by aggressive / non aggressive tumors.
Supplemental Table 1 from Educational Attainment and Cancer Incidence in a Large Nationwide Prospective Cohort
Authors: Hodge James M. , Patel Alpa V. , Islami Farhad , Jemal Ahmedin , Hiatt Robert A.
Published: December 2023

Supplemental Table 1 shows hazard ratios and 95% confidence intervals for male never smokers.
Data from Birth Defects in Offspring of Adolescent and Young Adults with a History of Cancer: A Population-Based Study of 27,000 Women
Authors: Murphy Caitlin C. , Betts Andrea C. , Pruitt Sandi L. , Cohn Barbara A. , Shay L. Aubree , Allicock Marlyn A. , Wang Jennifer S. , Lupo Philip J.
Published: December 2023

AbstractBackground:
We examined birth defects in offspring of adolescent and young adult (AYA) women with a history of cancer (age 15–39 years at diagnosis).
Methods:
We identified AYA women diagnosed with cancer between January 1, 1999, and December 31, 2015 using population-based data from the Texas Cancer Registry; data were linked with live birth and fetal death certificates through December 31, 2016 to identify singleton births to AYA women after diagnosis. Birth defects in offspring through age 12 months were ascertained from the Texas Birth Defects Registry. We estimated risk of birth defects in offspring of AYA women and women without cancer (matched 3:1 by maternal race/ethnicity, maternal age, and offspring year of birth) and compared risk using log binomial regression models.
Results:
There were 6,882 singleton births to AYA women after diagnosis. Common cancer types were thyroid (28.9%), lymphoma (12.5%), and breast (10.7%). Risk of any birth defect was higher in offspring of AYA women (6.0%) compared with offspring of women without cancer [n = 20,646; 4.8%; risk ratio (RR) 1.24; 95% confidence interval (CI), 1.11–1.38]. Risk of eye or ear (RR, 1.39; 95% CI, 1.03–1.90), heart and circulatory (RR, 1.32; 95% CI, 1.09–1.60), genitourinary (RR, 1.38; 95% CI, 1.12–1.69), and musculoskeletal (RR, 1.37; 95% CI, 1.13–1.66) defects was also higher.
Conclusions:
Risk of birth defects was elevated in liveborn and stillborn offspring of AYA women.
Impact:
Although birth defects are rare, AYA women making decisions about pregnancy and prenatal care should receive appropriate counseling and surveillance.
Data from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
Authors: Allen John M. , Awunti MegCholack , Guo Yi , Bian Jiang , Rogers Sherise C. , Scarton Lisa , DeRemer David L. , Wilkie Diana J.
Published: December 2023

AbstractBackground:
Supportive care medication use differences may contribute to racial disparities observed in health-related quality of life in patients with pancreatic cancer.
Methods:
In this observation study using the Surveillance, Epidemiology, and End Results-Medicare linked database, we sought to examine supportive care medication use disparities in patients with pancreatic cancer from 2005 to 2017 by race and ethnicity.
Results:
Among 74,309 patients included in the final analysis, racial and ethnic disparities in the use of supportive care medications were identified. After adjustment for confounding factors and compared with non-Hispanic Whites, minorities had significantly less use of opioids [Black: adjusted OR (aOR), 0.84; 95% confidence interval (CI), 0.79–0.88; Asian: aOR, 0.84; 95% CI, 0.79–0.90), and skeletomuscular relaxants (Black: aOR, 0.90; 95% CI, 0.82–0.99; Hispanic: aOR, 0.82; 95% CI, 0.74–0.91; Asian: aOR, 0.59; 95% CI, 0.51–0.68), and increased use of non-opioid analgesics (Hispanic: aOR, 1.16; 95% CI, 1.01–1.14; Asian: aOR, 1.37; 95% CI, 1.26–1.49). Racial and ethnic minorities had less use of antidepressants (Black: aOR, 0.56; 95% CI, 0.53–0.59; Hispanic: aOR, 0.77; 95% CI, 0.73–0.82; Asian: aOR, 0.47; 95% CI, 0.44–0.51), anxiolytics (Black: aOR, 0.78; 95% CI, 0.74–0.82; Hispanic: aOR, 0.66; 95% CI, 0.62–0.71; Asian: aOR, 0.52; 95% CI, 0.48–0.57), and antipsychotics (Hispanic: aOR, 0.90; 95% CI, 0.82–0.99; Asian: aOR, 0.84; 95% CI, 0.74–0.95).
Conclusions:
Racial and ethnic disparities in the use of supportive care medications among patients with pancreatic cancer were observed, with the differences unexplained by sociodemographic factors.
Impact:
Future studies should identify strategies to promote equitable use of supportive care medications among racial minorities and explore factors that may influence their use in these populations.
Supplemental Table S3 from Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
Authors: Hamadeh Issam S. , Patel Jai N. , Jacobs Ryan , Zeng Hang , He Jiaxian , Hu Bei , Moyo Tamara Kay , Soni Amy , Park Steven , Copelan Ed , Avalos Belinda , Hamilton Alicia , Steuerwald Nury , Ghosh Nilanjan
Published: December 2023

Table S3. Rates of CVSEs by genotype, Fisher’s Exact Test, and Logistic Regression results for all SNPs
Supplemental Table S2 from Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
Authors: Hamadeh Issam S. , Patel Jai N. , Jacobs Ryan , Zeng Hang , He Jiaxian , Hu Bei , Moyo Tamara Kay , Soni Amy , Park Steven , Copelan Ed , Avalos Belinda , Hamilton Alicia , Steuerwald Nury , Ghosh Nilanjan
Published: December 2023

Table S2. Frequencies of genotypes for each rsID
Supplemental Table S1 from Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
Authors: Hamadeh Issam S. , Patel Jai N. , Jacobs Ryan , Zeng Hang , He Jiaxian , Hu Bei , Moyo Tamara Kay , Soni Amy , Park Steven , Copelan Ed , Avalos Belinda , Hamilton Alicia , Steuerwald Nury , Ghosh Nilanjan
Published: December 2023

Table S1. Gene and rsIDs genotyped
Suppl Table S2 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Authors: Das Anirban , Tabori Uri , Sambira Nahum Lauren C. , Collins Natalie B. , Deyell Rebecca , Dvir Rina , Faure-Conter Cecile , Hassall Timothy E. , Minturn Jane E. , Edwards Melissa , Brookes Elissa , Bianchi Vanessa , Levine Adrian , Stone Simone C. , Sudhaman Sumedha , Sanchez Ramirez Santiago , Ercan Ayse B. , Stengs Lucie , Chung Jill , Negm Logine , Getz Gad , Maruvka Yosef E. , Ertl-Wagner Birgit , Ohashi Pamela S. , Pugh Trevor , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A.
Published: December 2023

Results of time-dependent co-variate and landmark analyses at time-points 3 and 6 months of the trial
Supplemental Figure S2 from Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
Authors: Hamadeh Issam S. , Patel Jai N. , Jacobs Ryan , Zeng Hang , He Jiaxian , Hu Bei , Moyo Tamara Kay , Soni Amy , Park Steven , Copelan Ed , Avalos Belinda , Hamilton Alicia , Steuerwald Nury , Ghosh Nilanjan
Published: December 2023

Figure S2. Linkage Disequilibrium Structures for KCNQ1 rs163182 and KCNQ1 rs2237895 single nucleotide polymorphisms
Suppl Figure S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Authors: Das Anirban , Tabori Uri , Sambira Nahum Lauren C. , Collins Natalie B. , Deyell Rebecca , Dvir Rina , Faure-Conter Cecile , Hassall Timothy E. , Minturn Jane E. , Edwards Melissa , Brookes Elissa , Bianchi Vanessa , Levine Adrian , Stone Simone C. , Sudhaman Sumedha , Sanchez Ramirez Santiago , Ercan Ayse B. , Stengs Lucie , Chung Jill , Negm Logine , Getz Gad , Maruvka Yosef E. , Ertl-Wagner Birgit , Ohashi Pamela S. , Pugh Trevor , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A.
Published: December 2023

Pathological complete remission in metastatic colorectal adenocarcinoma. (A) Baseline (hematoxylin-eosin, CD8 and PD-L1). (B) Post-nivolumab: no detectable tumor cells, increased inflammation, and increase in CD8 and PD-L1 expression. All IHC images are 100X.
Supplementary Tables 1-2 from Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes
Authors: Denu Ryan A. , Yang Richard K. , Lazar Alexander J. , Patel Shalin S. , Lewis Valerae O. , Roszik Jason , Livingston J. Andrew , Wang Wei-Lien , Shaw Kenna R. , Ratan Ravin , Zarzour Maria A. , Bird Justin , Raza Shaan , Akdemir Kadir C. , Rodon Ahnert Jordi , Subbiah Vivek , Patel Shreyaskumar , Conley Anthony P.
Published: December 2023

Supplementary Tables 1-2
Supplementary Figure 1 from Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
Authors: Lindskrog Sia V. , Birkenkamp-Demtröder Karin , Nordentoft Iver , Laliotis George , Lamy Philippe , Christensen Emil , Renner Derrick , Andreasen Tine G. , Lange Naja , Sharma Shruti , ElNaggar Adam C. , Liu Minetta C. , Sethi Himanshu , Aleshin Alexey , Agerbæk Mads , Jensen Jørgen B. , Dyrskjøt Lars
Published: December 2023

Longitudinal ctDNA data for NAC-treated patient cohort
Supplementary Figure S7 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Cox proportional-hazard analysis for the low-dose CM treatment effect on OS, DRFI and BCFI measures according to the Burstein molecular subtypes.
Supplementary Figure S5 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Kaplan-Meier estimates for OS, DRFI and BCFI measures between CM and no-CM cohorts across the TIME classification.
Supplementary Figure S3 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Kaplan-Meier estimates for OS, DRFI and BCFI measures between CM and no-CM cohorts across the Bareche TNBC molecular subtypes.
Supplementary Figure S1 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Authors: Joaquin Garcia Andrea , Rediti Mattia , Venet David , Majjaj Samira , Kammler Roswitha , Munzone Elisabetta , Gianni Lorenzo , Thürlimann Beat , Laáng István , Colleoni Marco , Loi Sherene , Viale Giuseppe , Regan Meredith M. , Buisseret Laurence , Rothé Françoise , Sotiriou Christos
Published: December 2023

Quality plots related to the low number of reads.
Supplementary Figure S5 from Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
Authors: Bessede Alban , Peyraud Florent , Le Moulec Sylvestre , Cousin Sophie , Cabart Mathilde , Chomy François , Rey Christophe , Lara Oren , Odin Ophélie , Nafia Imane , Guegan Jean-Philippe , Italiano Antoine
Published: December 2023

IDO1 activity inhibits T cell killing.
Table 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Authors: Ring Alistair , Kilburn Lucy S. , Pearson Alex , Moretti Laura , Afshari-Mehr Angelica , Wardley Andrew M. , Gurel Bora , Macpherson Iain R. , Riisnaes Ruth , Baird Richard D. , Martin Sue , Roylance Rebecca , Johnson Hannah , Ferreira Ana , Winter Matthew C. , Dunne Kathryn , Copson Ellen , Hickish Tamas , Burcombe Russell , Randle Kat , Serra Violeta , Llop-Guevara Alba , Bliss Judith M. , Turner Nicolas C.
Published: December 2023

Patients and characteristics.
Supplementary Figure S3 from Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
Authors: Bessede Alban , Peyraud Florent , Le Moulec Sylvestre , Cousin Sophie , Cabart Mathilde , Chomy François , Rey Christophe , Lara Oren , Odin Ophélie , Nafia Imane , Guegan Jean-Philippe , Italiano Antoine
Published: December 2023

Kaplan Meier curves of the progression-free survival of patients classified as High or Low according to their tumor CD163+ cell infiltration (A), stromal CD8+ cell infiltration (B) or tumor PDL1 expression (C).
Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

Complete KinomeScan results of HC-5404 assayed at 100, 1000, and 10000 nM.
Supplementary Figure S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Authors: Ring Alistair , Kilburn Lucy S. , Pearson Alex , Moretti Laura , Afshari-Mehr Angelica , Wardley Andrew M. , Gurel Bora , Macpherson Iain R. , Riisnaes Ruth , Baird Richard D. , Martin Sue , Roylance Rebecca , Johnson Hannah , Ferreira Ana , Winter Matthew C. , Dunne Kathryn , Copson Ellen , Hickish Tamas , Burcombe Russell , Randle Kat , Serra Violeta , Llop-Guevara Alba , Bliss Judith M. , Turner Nicolas C.
Published: December 2023

Figure S2. Progression free survival Kaplan Meier curve
Supplementary Fig. S4 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Authors: Stokes Michael E. , Calvo Veronica , Fujisawa Sho , Dudgeon Crissy , Huang Sharon , Ballal Nupur , Shen Leyi , Gasparek Jennifer , Betzenhauser Matthew , Taylor Simon J. , Staschke Kirk A. , Rigby Alan C. , Mulvihill Mark J. , Bose Nandita , Lightcap Eric S. , Surguladze David
Published: December 2023

Combining HC-5404 and VEGFR-TKIs does not affect mouse body weight or exposure levels in mouse.
Figure 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Authors: Ring Alistair , Kilburn Lucy S. , Pearson Alex , Moretti Laura , Afshari-Mehr Angelica , Wardley Andrew M. , Gurel Bora , Macpherson Iain R. , Riisnaes Ruth , Baird Richard D. , Martin Sue , Roylance Rebecca , Johnson Hannah , Ferreira Ana , Winter Matthew C. , Dunne Kathryn , Copson Ellen , Hickish Tamas , Burcombe Russell , Randle Kat , Serra Violeta , Llop-Guevara Alba , Bliss Judith M. , Turner Nicolas C.
Published: December 2023

Best percentage change from baseline for sum of the target lesions (n = 70).
Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Authors: Tang Tin-Yun , Nichetti Federico , Kaplan Ben , Lonardi Sara , Pietrantonio Filippo , Salvatore Lisa , Vivaldi Caterina , Rimassa Lorenza , de Braud Filippo , Rizzato Mario Domenico , Pavlick Dean , Chu Randy , Danner De Armas Anaemy , Sharaf Radwa , Sokol Ethan , Rodon Ahnert Jordi , Ross Jeffrey S. , Javle Milind , Niger Monica
Published: December 2023

Supplemental Table S5: Early Phase Clinical Trials of BRAF Dimer Inhibitors or Breakers
Supplementary Table 1 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

PI3Ki + MEKi + PORCNi therapy results in tumor clearance in Pb-Cre;PTENfl/flTrp53fl/fl mice
Supplementary Figure 9 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

Addition of PORCNi inhibits PI3Ki + MEKi mediated Wnt/β-catenin pathway activation in PTEN/p53-deficient GEMM tumor-derived PC cells
Supplementary Figure S2 from Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Authors: Tang Tin-Yun , Nichetti Federico , Kaplan Ben , Lonardi Sara , Pietrantonio Filippo , Salvatore Lisa , Vivaldi Caterina , Rimassa Lorenza , de Braud Filippo , Rizzato Mario Domenico , Pavlick Dean , Chu Randy , Danner De Armas Anaemy , Sharaf Radwa , Sokol Ethan , Rodon Ahnert Jordi , Ross Jeffrey S. , Javle Milind , Niger Monica
Published: December 2023

Figure S2: Overall Survival separated out by individual mutation classes.
Supplementary Figure 6 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

Direct treatment of TAM with PI3Ki/MEKi does not alter their phagocytic capacity
Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Authors: Tang Tin-Yun , Nichetti Federico , Kaplan Ben , Lonardi Sara , Pietrantonio Filippo , Salvatore Lisa , Vivaldi Caterina , Rimassa Lorenza , de Braud Filippo , Rizzato Mario Domenico , Pavlick Dean , Chu Randy , Danner De Armas Anaemy , Sharaf Radwa , Sokol Ethan , Rodon Ahnert Jordi , Ross Jeffrey S. , Javle Milind , Niger Monica
Published: December 2023

Figure S1: Progression Free Survival separated out by individual mutation classes
Supplementary Figure 5 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

Conditioned media from PI3Ki/MEKi-treated PC cells does not alter MHC-IIlo TAM histone lactylation and phagocytosis
Supplementary Figure 3 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

PI3Ki/MEKi combination therapy drives tumor control in majority of Pb-Cre;PTENfl/flTrp53fl/fl mice
Supplementary Figure 12 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

Conditioned media from PI3Ki + MEKi + PORCNi treated PTEN/p53-deficient tumor derived cells does not alter histone lactylation and phagocytic activity of MHC-IIlo TAM
Supplementary Figure 11 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Kelley Anne , Labadie Brian , Shafran Jordan , Rameshbabu Srikrishnan , Drovetsky Catherine , Bynoe Kaela , Solanki Ani , Markiewicz Erica , Fan Xiaobing , Loda Massimo , Patnaik Akash
Published: December 2023

Direct treatment of TAM with PI3Ki + MEKi + PORCNi therapy does not alter TAM phagocytic capacity
Supp Table 1 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Table 1. ATM mutations considered dysfunctional and supporting evidence
Supp Fig 7 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 7. Immune checkpoint inhibitor (ICI) monotherapy vs with chemotherapy in ATM-mutated patients.
Supp Fig 6 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 6. Clinical analyses in the FH-FMI CGDB cohort.
Study Representativeness Table1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
Authors: Chung David J. , Shah Nina , Wu Juan , Logan Brent , Bisharat Lina , Callander Natalie , Cheloni Giulia , Anderson Kenneth , Chodon Thinle , Dhakal Binod , Devine Steve , Somaiya Dutt Poorvi , Efebera Yvonne , Geller Nancy , Ghiasuddin Haider , Hematti Peiman , Holmberg Leona , Howard Alan , Johnson Bryon , Karagkouni Dimitra , Lazarus Hillard M. , Malek Ehsan , McCarthy Philip , McKenna David , Mendizabal Adam , Nooka Ajay , Munshi Nikhil , O'Donnell Lynn , Rapoport Aaron P. , Reese Jane , Rosenblatt Jacalyn , Soiffer Robert , Stroopinsky Dina , Uhl Lynne , Vlachos Ioannis S. , Waller Edmund K. , Young James W. , Pasquini Marcelo C. , Avigan David
Published: December 2023

Study representation of underserved communities
Supp Fig 2 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 2. ATM co-mutation enrichment analyses within cohorts.
Supp Fig 10 from ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Authors: Vokes Natalie I. , Galan Cobo Ana , Fernandez-Chas Margarita , Molkentine David , Treviño Santiago , Druker Vitaly , Qian Yu , Patel Sonia , Schmidt Stephanie , Hong Lingzhi , Lewis Jeff , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Lee J. Jack , Negrao Marcelo V. , Gibbons Don L. , Vaporciyan Ara , Le Xiuning , Wu Jia , Zhang Jianjun , Rigney Una , Iyer Sonia , Dean Emma , Heymach John V.
Published: December 2023

Supp Figure 10. ATM loss enhances STING signaling activation with chemotherapy in human cell lines.
Supplementary Material and Methods S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Authors: Jamieson Amy , Vermij Lisa , Kramer Claire J.H. , Jobsen Jan J. , Jürgemlienk-Schulz Ina , Lutgens Ludy , Mens Jan Willem , Haverkort Marie A.D. , Slot Annerie , Nout Remi A. , Oosting Jan , Carlson Joseph , Howitt Brooke E. , Ip Philip P.C. , Lax Sigurd F. , McCluggage W. Glenn , Singh Naveena , McAlpine Jessica N. , Creutzberg Carien L. , Horeweg Nanda , Gilks C. Blake , Bosse Tjalling
Published: December 2023

Supplementary material and methods
Supplementary Figure S5 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Authors: Jamieson Amy , Vermij Lisa , Kramer Claire J.H. , Jobsen Jan J. , Jürgemlienk-Schulz Ina , Lutgens Ludy , Mens Jan Willem , Haverkort Marie A.D. , Slot Annerie , Nout Remi A. , Oosting Jan , Carlson Joseph , Howitt Brooke E. , Ip Philip P.C. , Lax Sigurd F. , McCluggage W. Glenn , Singh Naveena , McAlpine Jessica N. , Creutzberg Carien L. , Horeweg Nanda , Gilks C. Blake , Bosse Tjalling
Published: December 2023

Recurrence-free survival by agreement on low-grade endometrioid morphology.
Supplementary Figure S4 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Authors: Jamieson Amy , Vermij Lisa , Kramer Claire J.H. , Jobsen Jan J. , Jürgemlienk-Schulz Ina , Lutgens Ludy , Mens Jan Willem , Haverkort Marie A.D. , Slot Annerie , Nout Remi A. , Oosting Jan , Carlson Joseph , Howitt Brooke E. , Ip Philip P.C. , Lax Sigurd F. , McCluggage W. Glenn , Singh Naveena , McAlpine Jessica N. , Creutzberg Carien L. , Horeweg Nanda , Gilks C. Blake , Bosse Tjalling
Published: December 2023

H&E, immunohistochemistry stains and relative copy number plot of a case diagnosed as low-grade EEC by ≥3 pathologists.
Supplementary Figure S3 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Authors: Jamieson Amy , Vermij Lisa , Kramer Claire J.H. , Jobsen Jan J. , Jürgemlienk-Schulz Ina , Lutgens Ludy , Mens Jan Willem , Haverkort Marie A.D. , Slot Annerie , Nout Remi A. , Oosting Jan , Carlson Joseph , Howitt Brooke E. , Ip Philip P.C. , Lax Sigurd F. , McCluggage W. Glenn , Singh Naveena , McAlpine Jessica N. , Creutzberg Carien L. , Horeweg Nanda , Gilks C. Blake , Bosse Tjalling
Published: December 2023

Predicted DNA ploidy.
Supplementary Figure S2 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Authors: Jamieson Amy , Vermij Lisa , Kramer Claire J.H. , Jobsen Jan J. , Jürgemlienk-Schulz Ina , Lutgens Ludy , Mens Jan Willem , Haverkort Marie A.D. , Slot Annerie , Nout Remi A. , Oosting Jan , Carlson Joseph , Howitt Brooke E. , Ip Philip P.C. , Lax Sigurd F. , McCluggage W. Glenn , Singh Naveena , McAlpine Jessica N. , Creutzberg Carien L. , Horeweg Nanda , Gilks C. Blake , Bosse Tjalling
Published: December 2023

Representative examples of cases diagnosed as low-grade EEC by ≤1 pathologists.
Supplementary Figure S2 from Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Authors: Rashidi Armin , Ebadi Maryam , Rehman Tauseef Ur , Elhusseini Heba , Kazadi David , Halaweish Hossam , Khan Mohammad H. , Hoeschen Andrea , Cao Qing , Luo Xianghua , Kabage Amanda J. , Lopez Sharon , Holtan Shernan G. , Weisdorf Daniel J. , Khoruts Alexander , Staley Christopher
Published: December 2023

Differential abundance analysis of pre- vs. post-dose genera in patients without grade II-IV aGVHD in the FMT arm
Supplementary Data S1 from Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Authors: Rashidi Armin , Ebadi Maryam , Rehman Tauseef Ur , Elhusseini Heba , Kazadi David , Halaweish Hossam , Khan Mohammad H. , Hoeschen Andrea , Cao Qing , Luo Xianghua , Kabage Amanda J. , Lopez Sharon , Holtan Shernan G. , Weisdorf Daniel J. , Khoruts Alexander , Staley Christopher
Published: December 2023

Supplementary data S1: LASSO results
Table S8 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Correlations between plasma concentration and relative dose intensity of lenvatinib
Supplementary Data F1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Authors: Johnson Margaret , Bell April , Lauing Kristen L. , Ladomersky Erik , Zhai Lijie , Penco-Campillo Manon , Shah Yajas , Mauer Elizabeth , Xiu Joanne , Nicolaides Theodore , Drumm Michael , McCortney Kathleen , Elemento Olivier , Kim Miri , Bommi Prashant , Low Justin T. , Memon Ruba , Wu Jennifer , Zhao Junfei , Mi Xinlei , Glantz Michael J. , Sengupta Soma , Castro Brandyn , Yamini Bakhtiar , Horbinski Craig , Baker Darren J. , Walunas Theresa L. , Schiltz Gary E. , Lukas Rimas V. , Wainwright Derek A.
Published: December 2023

Supplementary Figures
Table S6 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Subsequent anti-cancer treatment after lenvatinib
Table S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Radiological assessments according to both mRECIST and RECIST 1.1 (evaluation by central review)
Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Radiological assessments according to RECIST 1.1 (evaluation by each investigator)
Table S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Cause of dose modifications and treatment discontinuations due to adverse events
Figure S6 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Authors: Kobayashi Kazufumi , Ogasawara Sadahisa , Maruta Susumu , Okubo Tomomi , Itokawa Norio , Haga Yuki , Seko Yuya , Moriguchi Michihisa , Watanabe Shunji , Shiko Yuki , Takatsuka Hirokazu , Kanzaki Hiroaki , Koroki Keisuke , Inoue Masanori , Nakamura Masato , Kiyono Soichiro , Kanogawa Naoya , Kondo Takayuki , Suzuki Eiichiro , Ooka Yoshihiko , Nakamoto Shingo , Inaba Yosuke , Ikeda Masafumi , Okabe Shinichiro , Morimoto Naoki , Itoh Yoshito , Nakamura Kazuyoshi , Ito Kenji , Azemoto Ryosaku , Atsukawa Masanori , Itobayashi Ei , Kato Naoya
Published: December 2023

Association between portal hypertension and relative dose intensity of lenvatinib